S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

ABOS Acumen Pharmaceuticals Inc

3.13

-0.06 (-1.88%)

27 Apr 2024 - Closed

Delayed by 15 minutes

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

null

Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Mar 2024 to Apr 2024

Click Here for more Acumen Pharmaceuticals Charts.

Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Apr 2023 to Apr 2024

Click Here for more Acumen Pharmaceuticals Charts.

Acumen Pharmaceuticals Inc News

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Tuesday 16 April 2024 (2 weeks ago) • GlobeNewswire Inc.

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
Thursday 4 April 2024 (3 weeks ago) • GlobeNewswire Inc.

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
Tuesday 26 March 2024 (1 month ago) • GlobeNewswire Inc.

Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
Thursday 21 March 2024 (1 month ago) • GlobeNewswire Inc.

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
Wednesday 20 March 2024 (1 month ago) • GlobeNewswire Inc.

Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
Wednesday 13 March 2024 (2 months ago) • GlobeNewswire Inc.

Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
Saturday 9 March 2024 (2 months ago) • GlobeNewswire Inc.

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
Thursday 22 February 2024 (2 months ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Thursday 15 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 2 February 2024 (3 months ago) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Friday 2 February 2024 (3 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 1 February 2024 (3 months ago) • Edgar (US Regulatory)

More Acumen Pharmaceuticals Inc News Articles

AUD vs US Dollar

S&P ASX 300 Metals and M...

Gold vs US Dollar

Verizon Communications

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions